Skip to main content

Advertisement

SpringerLink
Log in

Idarucizumab in major trauma patients: a single centre real life experience

  • Original Article
  • Published:
European Journal of Trauma and Emergency Surgery Aims and scope Submit manuscript

Abstract

Introduction

Trauma care providers are facing an increasing number of elderly patients on direct oral anticoagulants prior to injury. For dabigatran etexilate (DAB), the specific antagonist idarucizumab (IDA) has been approved since 2015 as a reversal agent. However, only limited data regarding the use of IDA in trauma patients are available.

Methods

We performed a retrospective analysis of trauma patients under DAB for whom IDA administration was deemed necessary to reverse DAB’s antithrombotic effect.

Results

A total of 15 (9 male) patients were treated with IDA during the study period. The mean age was 81 ± 10 years. Intracranial haemorrhage (n = 7) and long bone fractures (n = 5) were the most common types of injury. Three patients were diagnosed as polytrauma. In all but one patient, atrial fibrillation was the indication for DAB intake. The median dose of IDA was 2.5 g (IQR 2.5–5). IDA administration decreased DAB plasma levels from 112.4 (IQR 73.4–123.4) to 5 (IQR 4–12) ng/mL (p = 0.031), thrombin time from 114.8 ± 48.3 to 16.2 ± 0.5 s (p < 0.0001) and activated partial thromboplastin time form 45.4 ± 11.3 to 34.2 ± 7.0 s (p = 0.0025). No thromboembolic events or side effects attributed to IDA were observed. All patients survived until hospital discharge.

Conclusions

In trauma patients under DAB prior to injury, IDA decreased DAB plasma levels and normalized coagulation parameters. IDA appears to be safe, and no serious side effects were observed in this small cohort of patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Wood B, Nascimento B, Rizoli S, Sholzberg M, McFarlan A, Phillips A, Ackery AD. The anticoagulated trauma patient in the age of the direct oral anticoagulants: a Canadian perspective. Scand J Trauma Resusc Emerg Med. 2017;25:76.

    Article  Google Scholar 

  2. Bruckbauer M, Prexl O, Voelckel W, Ziegler B, Grottke O, Maegele M, Schöchl H. Impact of direct oral anticoagulants (DOACs) in patients with hip fractures. J Orthop Trauma. 2019;33:e8–e13.

    Article  Google Scholar 

  3. Coleman J, Baldawi M, Heidt D. The effect anticoagulation status on geriatric fall trauma patients. Am J Surg. 2016;212:1237–42.

    Article  Google Scholar 

  4. Chai-Adisaksopha C, Crowther M, Isayama T, Lim W. The impact of bleeding complications in patients receiving target-specific oral anticoagulants: a systematic review and meta-analysis. Blood. 2014;124:2450–8.

    Article  CAS  Google Scholar 

  5. Barnes GD, Lucas E, Alexander GC, Goldberger ZD. National trends in ambulatory oral anticoagulant use. Am J Med. 2015;128(1300–5):e2.

    Google Scholar 

  6. Prexl O, Bruckbauer M, Voelckel W, Ziegler B, Grottke O, Maegele M, Schöchl H. The impact of direct oral anticoagulants in traumatic brain injury patients greater than 60-years-old. Scan J Trauma Resus Emerg Med. 2018;26:20.

    Article  Google Scholar 

  7. Maung AA, Bhattacharya B, Schuster KM, Davis KA. Trauma patients on new oral anticoagulation agents have lower mortality than those on warfarin. J Trauma Acute Care Surg. 2016;81:652–7.

    Article  CAS  Google Scholar 

  8. Feeney JM, Neulander M, DiFiori M, Kis L, Shapiro DS, Jayaraman V, et al. Direct oral anticoagulants compared with warfarin in patients with severe blunt trauma. Injury. 2017;48:47–50.

    Article  Google Scholar 

  9. Maegele M, Grottke O, Schöchl H, Sakowitz OA, Spannagl M, Koscielny J. Direct oral anticoagulants in emergency trauma admissions. Dtsch Arztebl Int. 2016;113:575–82.

    PubMed  PubMed Central  Google Scholar 

  10. Levy JH, Douketis J, Weitz JI. Reversal agents for non-vitamin K antagonist oral anticoagulants. Nat Rev Cardiol. 2018;15:273–81.

    Article  CAS  Google Scholar 

  11. Connolly SJ, Crowther M, Eikelboom JW, Gibson CM, Curnutte JT, Lawrence JH, et al. Full study report of andexanet alfa for bleeding associated with factor Xa inhibitors. N Engl J Med. 2019;380:1326–35.

    Article  CAS  Google Scholar 

  12. Siegal DM, Curnutte JT, Connolly SJ, Lu G, Conley PB, Wiens BL, et al. Andexanet alfa for the reversal of factor Xa inhibitor activity. N Engl J Med. 2015;373:2413–24.

    Article  CAS  Google Scholar 

  13. Hunt BJ, Neal MD, Stensballe J. Reversing anti-factor Xa agents and the unmet needs in trauma patients. Blood. 2018;132:2441–5.

    Article  CAS  Google Scholar 

  14. https://www.drugs.com/newdrugs/fda-approves-praxbind-idarucizumab-reversal-agent-anticoagulant-pradaxa-4278.html. Accessed 16 Oct 2015.

  15. Eikelboom JW, Quinlan DJ, van Ryn J, Weitz JI. Idarucizumab: the antidote for reversal of dabigatran. Circulation. 2015;132:2412–22.

    Article  Google Scholar 

  16. Pollack CV Jr, Reilly PA, van Ryn J, Eikelboom JW, Glund S, Bernstein RA, et al. Idarucizumab for dabigatran reversal—full cohort analysis. N Engl J Med. 2017;377:431–41.

    Article  CAS  Google Scholar 

  17. Vosko MR, Bocksrucker C, Drwiła R, Dulíček P, Hauer T, Mutzenbach J, et al. Real-life experience with the specific reversal agent idarucizumab for the management of emergency situations in dabigatran-treated patients: a series of 11 cases. J Thromb Thrombolysis. 2017;43:306–17.

    Article  CAS  Google Scholar 

  18. Brennan Y, Favaloro EJ, Pasalic L, Keenan H, Curnow J. Lessons learnt from local real-life experience with idarucizumab for the reversal of dabigatran. Intern Med J. 2019;49:59–655.

    Article  CAS  Google Scholar 

  19. Sheikh-Taha M. Idarucizumab for reversal of dabigatran: single-center real-world experience. Am J Cardiovasc Drugs. 2019;19:59–64.

    Article  CAS  Google Scholar 

  20. Raco V, Ahuja T, Green D. Assessment of patients post reversal with idarucizumab. J Thromb Thrombolysis. 2018;46:466–72.

    Article  CAS  Google Scholar 

  21. Tsai YT, Hsiao YJ, Tsai LK, Yen PS, Lin FY, Lu CH, Fang CW. Idarucizumab-facilitated intravenous thrombolysis in acute stroke with dabigatran: two cases with hemorrhagic transformation. J Neurol Sci. 2018;388:155–7.

    Article  Google Scholar 

  22. Van der Wall SJ, van Rein N, van den Bemt B, Kruip MJHA, Meijer K, Te Boome LCJ, et al. Performance of idarucizumab as antidote of dabigatran in daily clinical practice. Europace. 2019;21:414–20.

    Article  Google Scholar 

  23. Clegg A, Young J, Iliffe S, Rikkert MO, Rockwood K. Frailty in elderly people. Lancet. 2013;381:752–62.

    Article  Google Scholar 

  24. Joseph B, Pandit V, Zangbar B, Kulvatunyou N, Khalil M, Tang A, et al. Superiority of frailty over age in predicting outcomes among geriatric trauma patients: a prospective analysis. JAMA Surg. 2014;149:766–72.

    Article  Google Scholar 

  25. Calabria S, Forcesi E, Dondi L, Pedrini A, Maggioni AP, Martini N. Target population of non-deferrable surgery and uncontrolled severe bleeding related to dabigatran. Cardiovasc Drugs Ther. 2018;32:281–6.

    Article  CAS  Google Scholar 

  26. Kudo D, Kushimoto S, Shiraishi A, Ogura H, Hagiwara A, Saitoh D. J-OCTET Investigators The impact of preinjury antithrombotic medication on hemostatic interventions in trauma patients. Am J Emerg Med. 2017;35:62–5.

    Article  Google Scholar 

  27. Nishijima DK, Shahlaie K, Sarkar K, Rudisill N, Holmes JF. Risk of unfavorable long-term outcome in older adults with traumatic intracranial hemorrhage and anticoagulant or antiplatelet use. Am J Emerg Med. 2013;31:1244–7.

    Article  Google Scholar 

  28. Gardner RC, Dams-O'Connor K, Morrissey MR, Manley GT. Geriatric traumatic brain injury: epidemiology, outcomes, knowledge gaps, and future directions. J Neurotrauma. 2018. https://doi.org/10.1089/neu.2017.5371.

    Article  PubMed  PubMed Central  Google Scholar 

  29. Wiegele M, Schöchl H, Haushofer A, Ortler M, Leitgeb J, Kwasny O, et al. Diagnostic and therapeutic approach in adult patients with traumatic brain injury receiving oral anticoagulant therapy: an Austrian interdisciplinary consensus statement. Crit Care. 2019;22(23):62.

    Article  Google Scholar 

  30. Van Ryn J, Grottke O, Spronk HM. Measurement of dabigatran in standardly used clinical assays, whole blood viscoelastic coagulation and thrombin generation. Clin Lab Med. 2014;34:479–501.

    Article  Google Scholar 

  31. Hawes EM, Deal AM, Funk-Adcock D, Gosselin R, Jeanneret C, Cook AM, et al. Performance of coagulation tests in patients on therapeutic doses of dabigatran: a cross-sectional pharmacodynamic study based on peak and trough plasma levels. J Thromb Haemost. 2013;11:1493–502.

    Article  CAS  Google Scholar 

  32. Pincus D, Ravi B, Wasserstein D, Huang A, Paterson JM, Nathens AB, et al. Association between wait time and 30-day mortality in adults undergoing hip fracture surgery. JAMA. 2017;318:1994–2003.

    Article  Google Scholar 

  33. Product information: Idarucizumab. https://www.tga.gov.au/sites/default/files/auspar-idarucizumab-161025-pi.pdf. Accessed 25 Oct 2016.

  34. Hegemann I, Ganter C, Widmer CC, Becker M, Müller D, Spahn DR. Ongoing redistribution of dabigatran necessitates repetitive application of idarucizumab. Br J Anaesth. 2018;121:505–8.

    Article  CAS  Google Scholar 

  35. Simon A, Domanovits H, Ay C, Sengoelge G, Levy JH, Spiel AO. The recommended dose of idarucizumab may not always be sufficient for sustained reversal of dabigatran. J Thromb Haemost. 2017;15:1317–21.

    Article  CAS  Google Scholar 

  36. Vornicu O, Larock AS, Dincq AS, Douxfils J, Dogné JM, Mullier F, Lessire S. Idarucizumab for the treatment of hemorrhage and dabigatran reversal in patients requiring urgent surgery or procedures. Expert Opin Biol Ther. 2017;17:1275–9126126.

    Article  CAS  Google Scholar 

  37. Honickel M, Braunschweig T, Rossaint R, Stoppe C, ten Cate H, Grottke O. Reversing dabigatran anticoagulation with prothrombin complex concentrate versus idarucizumab as part of multimodal hemostatic intervention in an animal model of polytrauma. Anesthesiology. 2017;127:852–61.

    Article  CAS  Google Scholar 

  38. Chaussade E, Hanon O, Boully C, Labourée F, Caillard L, Gerotziafas G, et al. Real-life peak and trough dabigatran plasma measurements over time in hospitalized geriatric patients with atrial fibrillation. J Nutr Health Aging. 2018;22:165–73.

    Article  CAS  Google Scholar 

  39. Gerner ST, Kuramatsu JB, Sembill JA, Sprügel MI, Endres M, Haeusler KG, et al. Association of prothrombin complex concentrate administration and hematoma enlargement in non-vitamin K antagonist oral anticoagulant-related intracerebral hemorrhage. Ann Neurol. 2018;83:186–96.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We would like to thank Lisa Sandner and her team from the Central Laboratory of the AUVA Trauma Centre Salzburg for their ambitiously assistance in running some of the analyses.

Funding

This study was funded by hospital resources.

Author information

Authors and Affiliations

  1. Departement of Anaesthesiology and Intensive Care Medicine AUVA Trauma Centre Salzburg, Academic Teaching Hospital of the Paracelsus Medical University, Dr. Franz-Rehrl-Platz 5, 5020, Salzburg, Austria

    Daniel Oberladstätter, Wolfgang Voelckel, Martin Bruckbauer & Herbert Schöchl

  2. Ludwig Boltzmann Institute for Experimental and Clinical Traumatology, AUVA Trauma Research Centre, Vienna, Austria

    Johannes Zipperle & Herbert Schöchl

  3. Department of Anaesthesiology, RWTH Aachen University Hospital, Aachen, Germany

    Oliver Grottke

  4. Departement of Anaesthesiology and Intensive Care Medicine, University Hospital of Paracelsus Medical Private University, Salzburg, Austria

    Bernhard Ziegler

Authors
  1. Daniel Oberladstätter
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Wolfgang Voelckel
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Martin Bruckbauer
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Johannes Zipperle
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Oliver Grottke
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Bernhard Ziegler
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Herbert Schöchl
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Conception and design: D.O., B.Z., and H.S. Data extraction: D.O., M.B. Data analysis: H.S., W.V., O.G., J.Z., D.O. Drafting the manuscript: H.S., D.O., W.V., B.Z. and O.G. All authors critically reviewed the manuscript and agreed to the final version.

Corresponding author

Correspondence to Herbert Schöchl.

Ethics declarations

Conflict of interest

H. S. has received honoraria for participation in advisory board meetings for Bayer Healthcare, Böhringer Ingelheim and Tem International, and has received study Grants from CSL Behring. O. G. has received study Grants from CSL Behring, Portola, TEM International. B. Z. has received speaker fees from CSL Behring. D. O., J. Z., and M. B. declare no conflict of interest.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary file1 (PDF 91 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Oberladstätter, D., Voelckel, W., Bruckbauer, M. et al. Idarucizumab in major trauma patients: a single centre real life experience. Eur J Trauma Emerg Surg 47, 589–595 (2021). https://doi.org/10.1007/s00068-019-01233-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00068-019-01233-y

Keywords

Search

Navigation